Malignant Female Reproductive System Neoplasm

Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,464
Recruiting: 821
Ph III recruiting: 96
Growth YoY: +6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (740)

clinicaltrialsPublishedShowing 351–400 of 1,053 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05071937	ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer	recruiting	Phase 2	33	Alexander B Olawaiye, MDOTHER	1	Jun 18, 2026	clinicaltrials
NCT05538091	Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	recruiting	Phase 2	48	Ronald BuckanovichOTHER	1	Jun 18, 2026	clinicaltrials